Aeson Therapeutics' Acquisition

Aeson Therapeutics was acquired by acquirer and Hollis-Eden Pharmaceuticals on May 24, 2006.

Dehydroepiandrosterone (DHEA) may have therapeutic uses against cardiovascular disease, immune disorders, cancer and other diseases, but the hormone is a precursor of androgens and estrogens and can c…

Articles about Aeson Therapeutics' Acquisition: